Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NEAL V PALEJWALA

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1871720755
CMS profile
815116
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$14,279.13

82 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,885.00 3
Food and Beverage $5,545.81 75
Travel and Lodging $1,458.32 3
Honoraria $1,390.00 1

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NEAL V PALEJWALA

NPI 1871720755 · CMS profile ID 815116

Allopathic & Osteopathic Physicians / Ophthalmology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871720755?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NEAL V PALEJWALA, NPI 1871720755, CMS profile ID 815116. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871720755?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). NEAL V PALEJWALA, NPI 1871720755, CMS profile ID 815116. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871720755?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
NEAL V PALEJWALA, NPI 1871720755, CMS profile ID 815116, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–82 of 82 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1871720755?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

82 matching records · $14,279.13 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 82 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–82 of 82.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $2,115.0006/18/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133079546 CMS
Regeneron Healthcare Solutions, Inc. $33.4706/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114129778 CMS
Bausch & Lomb Americas Inc. $21.2606/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140418803 CMS
Bausch & Lomb Americas Inc. $21.7805/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140418801 CMS
Alimera Sciences, Inc. $108.2005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092840106 CMS
Dutch Ophthalmic, USA $119.8905/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154792276 CMS
Bausch & Lomb Americas Inc. $20.7705/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1140418799 CMS
Genentech USA, Inc. $29.4305/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133079535 CMS
Regeneron Healthcare Solutions, Inc. $28.6805/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114129776 CMS
Astellas Pharma US Inc $32.0105/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139359575 CMS
Apellis Pharmaceuticals, Inc. $21.5705/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154027085 CMS
Genentech USA, Inc. $6.3005/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133079531 CMS
Genentech USA, Inc. $7.8905/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133079526 CMS
Genentech USA, Inc. $32.1204/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133079523 CMS
Alimera Sciences, Inc. $1,390.0004/18/2024 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092833516 CMS
Regeneron Healthcare Solutions, Inc. $34.5604/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114129774 CMS
Regeneron Healthcare Solutions, Inc. $28.3504/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114129772 CMS
Astellas Pharma US Inc $23.9004/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139331798 CMS
Regeneron Healthcare Solutions, Inc. $121.6503/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114129770 CMS
RxSight Inc $115.8503/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144224214 CMS
Biogen, Inc. $28.4003/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104863884 CMS
Genentech USA, Inc. $33.1203/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133079539 CMS
Alimera Sciences, Inc. $425.1503/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092840501 CMS
ABBVIE INC. $15.9002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105171594 CMS
Genentech, Inc. $104.9102/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133079515 CMS
Regeneron Healthcare Solutions, Inc. $28.6202/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114129768 CMS
Apellis Pharmaceuticals, Inc. $20.5702/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154027083 CMS
Regeneron Healthcare Solutions, Inc. $26.1702/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114129766 CMS
Regeneron Healthcare Solutions, Inc. $25.0101/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114129764 CMS
ABBVIE INC. $13.9201/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105171592 CMS
Genentech USA, Inc. $34.3901/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133079518 CMS
Alimera Sciences, Inc. $344.3301/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092829177 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,183.65 13
PY2020 $166.28 6
PY2021 $887.00 21
PY2022 $2,709.40 37
PY2023 $4,217.52 51
PY2024 $14,279.13 82
PY2025 $10,006.22 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $336,758.49 235
PY2024 Principal investigator $28,329.70 35
PY2022 Principal investigator $8,940.00 1
PY2021 Principal investigator $57,714.23 3
PY2020 Principal investigator $141,402.64 9
PY2019 Principal investigator $20,845.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

235 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $1,618.20 12/24/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238653
Principal investigator 1 Genentech, Inc. $2,703.00 12/19/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211647280
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,251.69 12/19/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278526
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,663.83 12/19/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184278528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266587
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266589
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266591
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266593
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266595
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266597
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.80 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266599
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266603
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $194.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266613
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266615
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.80 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266617
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.60 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266619
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266623
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266627
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266631
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266637
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266639
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266643
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $194.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266645
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 11/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184266647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,359.42 11/27/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184265895
Principal investigator 1 Ocular Therapeutix, Inc. $4,842.00 11/21/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238651
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,496.57 11/19/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262351
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,384.69 11/19/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262353
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $977.55 11/19/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184262355
Principal investigator 1 Genentech, Inc. $11,278.00 11/12/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211647276
Principal investigator 1 Ocular Therapeutix, Inc. $1,631.70 11/12/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238647
Principal investigator 1 Ocular Therapeutix, Inc. $6,877.89 11/12/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238649
Principal investigator 1 Ocular Therapeutix, Inc. $12,266.10 10/22/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238645
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,359.42 10/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,663.83 10/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251339
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,384.69 10/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251341
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,496.57 10/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184251343
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647171
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647176
Principal investigator 1 F. Hoffmann-La Roche AG $81.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647181
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647185
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647189
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647193
Principal investigator 1 F. Hoffmann-La Roche AG $81.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647197
Principal investigator 1 F. Hoffmann-La Roche AG $34.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647200
Principal investigator 1 F. Hoffmann-La Roche AG $1,204.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647204
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647208
Principal investigator 1 F. Hoffmann-La Roche AG $1,204.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647211
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647215
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647220
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 10/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647224
Principal investigator 1 ABBVIE INC. $5,690.10 10/01/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202512986
Principal investigator 1 Ocular Therapeutix, Inc. $16,552.70 10/01/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238643
Principal investigator 1 Ocular Therapeutix, Inc. $1,618.20 09/24/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19.60 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.80 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239110
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,062.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,793.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239120
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $357.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19.60 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $223.20 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239132
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239134
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239136
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239138
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239140
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239146
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $61.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $800.80 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239150
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $462.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $53.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $110.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239160
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $194.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239164
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239170
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239172
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239174
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $194.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239178
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $81.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239180
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $146.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $105.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $94.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $51.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239194
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239196
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $78.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239198
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $49.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239200
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239202
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $67.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239206
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $143.00 09/17/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1184239212
Principal investigator 1 Ocular Therapeutix, Inc. $25.02 09/12/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238639
Principal investigator 1 Ocular Therapeutix, Inc. $17,619.00 09/03/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238635
Principal investigator 1 Ocular Therapeutix, Inc. $6,395.78 09/03/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238637
Principal investigator 1 ABBVIE INC. $8,843.90 08/27/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506089
Principal investigator 1 Ocular Therapeutix, Inc. $1,618.20 08/27/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238633
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 08/22/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647128
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 08/22/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647136
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 08/22/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647144
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 08/22/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647154
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 08/22/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647161
Principal investigator 1 Genentech, Inc. $11,285.00 08/22/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211647267
Principal investigator 1 Astellas Pharma Global Development $1,432.00 08/20/2025 Non-covered Recipient Entity
Retinal Research Institute LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185559
Principal investigator 1 Astellas Pharma Global Development $1,432.00 08/20/2025 Non-covered Recipient Entity
Retinal Research Institute LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185561
Principal investigator 1 Ocular Therapeutix, Inc. $24,170.00 08/20/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238631
Principal investigator 1 Ocular Therapeutix, Inc. $4,592.30 08/13/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238627
Principal investigator 1 Ocular Therapeutix, Inc. $9,855.90 08/13/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238629
Principal investigator 1 Astellas Pharma Global Development $7,793.00 08/11/2025 Non-covered Recipient Entity
Retinal Research Institute LLC
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration No dispute reported 06/30/2026 1234185563
Principal investigator 1 F. Hoffmann-La Roche AG $4,225.00 08/01/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647140
Principal investigator 1 Genentech, Inc. $15,770.00 08/01/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211647272
Principal investigator 1 ABBVIE INC. $3,094.80 07/25/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202499798
Principal investigator 1 Ocular Therapeutix, Inc. $1,618.20 07/25/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238625
Principal investigator 1 Genentech, Inc. $11,129.00 07/23/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211647263
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 07/21/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647131
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 07/21/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647146
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 07/21/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647149
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 07/21/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647158
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 07/21/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647167
Principal investigator 1 Ocular Therapeutix, Inc. $2,728.35 07/04/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238623
Principal investigator 1 Ocular Therapeutix, Inc. $4,012.20 07/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238619
Principal investigator 1 Ocular Therapeutix, Inc. $21,105.00 07/02/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238621
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 06/18/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646972
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 06/18/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646975
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 06/18/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646982
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 06/18/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647085
Principal investigator 1 F. Hoffmann-La Roche AG $1,204.00 06/18/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647113
Principal investigator 1 F. Hoffmann-La Roche AG $1,500.00 06/16/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647004
Principal investigator 1 Genentech, Inc. $273.00 06/06/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211647251
Principal investigator 1 Genentech, Inc. $645.00 06/06/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211647256
Principal investigator 1 Genentech, Inc. $156.00 06/06/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
A Phase 1 SAD MD in Diabetic Macular Edema No dispute reported 06/30/2026 1211647259
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 06/04/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238611
Principal investigator 1 Ocular Therapeutix, Inc. $1,618.20 05/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238607
Principal investigator 1 Ocular Therapeutix, Inc. $9,825.30 05/28/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238609
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 05/21/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238605
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/16/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646912
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/16/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646920
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/16/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647026
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/16/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647030
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/16/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647043
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/16/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647072
Principal investigator 1 Ocular Therapeutix, Inc. $11,567.70 05/09/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238603
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646895
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646899
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646903
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646907
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646917
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646923
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646926
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646930
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646934
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646937
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646941
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646947
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646951
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646956
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646960
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646964
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646967
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646979
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646985
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646988
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646992
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646995
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211646998
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647007
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647010
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647015
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647020
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647034
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647038
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647047
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647051
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647055
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647060
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647064
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647067
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647076
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647080
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647088
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647091
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647095
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647101
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647105
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647109
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647115
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647119
Principal investigator 1 F. Hoffmann-La Roche AG $239.00 05/07/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
REAL WORLD LONG TERM DATA COLLECTION FOR ROCHE OPHTHALMOLOGY PRODUCTS VOYAGER No dispute reported 06/30/2026 1211647124
Principal investigator 1 Ocular Therapeutix, Inc. $1,618.20 04/30/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238599
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 04/30/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238601
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 04/09/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238597
Principal investigator 1 Ocular Therapeutix, Inc. $1,618.20 03/26/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238617
Principal investigator 1 Ocular Therapeutix, Inc. $150.00 03/14/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238615
Principal investigator 1 Ocular Therapeutix, Inc. $12,096.00 03/12/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238613
Principal investigator 1 Ocular Therapeutix, Inc. $3,236.40 02/05/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238589
Principal investigator 1 Ocular Therapeutix, Inc. $144.00 01/29/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238591
Principal investigator 1 Ocular Therapeutix, Inc. $75.00 01/29/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238593
Principal investigator 1 Ocular Therapeutix, Inc. $31.49 01/29/2025 Non-covered Recipient Entity
RETINAL RESEARCH INSTITUTE LLC
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250238595